


10058-F4

Cat. No.:	HY-12702
CAS No.:	403811-55-2
Molecular Formula:	C ₁₂ H ₁₁ NOS ₂
Molecular Weight:	249.35
Target:	c-Myc; Autophagy
Pathway:	Apoptosis; Autophagy
Storage:	Powder -20°C 3 years 4°C 2 years



* The compound is unstable in solutions, freshly prepared is recommended.

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 41 mg/mL (164.43 mM)
* "≥" means soluble, but saturation unknown.

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	4.0104 mL	20.0521 mL	40.1043 mL
	5 mM	0.8021 mL	4.0104 mL	8.0209 mL
	10 mM	0.4010 mL	2.0052 mL	4.0104 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 0.83 mg/mL (3.33 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

In Vitro

10058-F4 inhibits growth of leukemic cells and dimerization of Myc and Max. 10058-F4 induces cell-cycle arrest and apoptosis of AML cells. 10058-F4 arrests AML cells at G0/G1 phase, downregulates c-Myc expression and upregulated CDK inhibitors, p21 and p27. Meanwhile, 10058-F4 induces apoptosis through activation of mitochondrial pathway shown by downregulation of Bcl-2, upregulation of Bax, release of cytoplasmic cytochrome C, and cleavage of caspase 3, 7, and 9. Furthermore, 10058-F4 also induces myeloid differentiation, possibly through activation of multiple transcription factors. Similarly, 10058-F4-induced apoptosis and differentiation could also be observed in primary AML cells^[1]. 10058-F4

decreases c-Myc protein levels, inhibits proliferation of HepG2 cells likely through upregulation of cyclin-dependent kinase (cdk) inhibitor, p21WAF1 and lowers intracellular levels of [alpha]-fetoprotein (AFP). Treatment with 10058-F4 also downregulates human telomerase reverse transcriptase (hTERT) at the transcriptional level. In addition to inhibiting the proliferation of HepG2 cells, 10058-F4 enhances sensitivity to conventional chemotherapeutic agents, doxorubicin, 5-fluorouracil (5-FU) and cisplatin^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Peak plasma 10058-F4 concentrations of approximately 300 μ M are seen at 5 min and declined to below the detection limit at 360 min following a single iv dose. Plasma concentration versus time data are best approximated by a two-compartment, open, linear model. The highest tissue concentrations of 10058-F4 are found in fat, lung, liver, and kidney. Peak tumor concentrations of 10058-F4 are at least tenfold lower than peak plasma concentrations. Eight metabolites of 10058-F4 are identified in plasma, liver, and kidney. The terminal half-life of 10058-F4 is approximately 1 h, and the volume of distribution is > 200 mL/kg. No significant inhibition of tumor growth is seen after i.v. treatment of mice with either 20 or 30 mg/kg 10058-F4^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[1]

Cells, plated in 96-well plates (10^5 /mL for cell lines and 5×10^5 /mL for primary leukemic cells), are treated in triplicate with indicated concentrations of 10058-F4. At various time points, 20 μ L 5 mg/mL MTT is added to each well. After incubation at 37°C for 3 hours, the MTT medium is removed and 100 μ L DMSO lysis buffer is added. The number of viable cells is assessed by the percentage of absorbance of treated cells relative to that of solvent controls, using 570-nm wavelength on a spectrophotometer.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[3]

C B-17 SCID mice bearing PC-3 human prostate tumor xenografts are stratified into the following groups: Control, vehicle control, positive control (docetaxel, 10 mg/kg), and 10058-F4 treatment (20 or 30 mg/kg/dose). Previous studies by us indicates that 30 mg/kg is the maximally tolerated dose of 10058-F4 on this schedule. Mice are treated i.v. daily for 5 days for 2 weeks, and body weights and tumor volumes are recorded twice weekly. In the second study, C B-17 SCID mice bearing DU145 human androgen-independent prostate cancer xenografts are stratified to similar treatment groups. Docetaxel serves as the positive control for both efficacy studies and is administered i.v. every 7 days for two doses of 10 mg/kg. Tumors are measured with calipers, and tumor volumes are calculated using the formula: $TV = L \times W^2 / 2$ where L is the largest diameter of the tumor and W is the smallest diameter perpendicular to L. Mice are followed for at least 1 week following the completion of the dosing so that tumor regrowth could be monitored.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Hematol Oncol. 2020 Feb 5;13(1):11.
- Oncogene. 2020 Apr;39(16):3354-3366.
- Mol Oncol. 2018 Dec;12(12):2191-2208
- Cell Death Dis. 2020 Nov 15;11(11):982.
- Cell Death Dis. 2018 Feb 22;9(3):307.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Huang MJ, et al. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. *Exp Hematol*. 2006 Nov;34(11):1480-9.

[2]. Lin CP, et al. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. *Anticancer Drugs*. 2007 Feb;18(2):161-70.

[3]. Guo J, et al. Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidene]-2-thioxothiazolidin-4-one, in mice. *Cancer Chemother Pharmacol*. 2009 Mar;63(4):615-25

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA